Collecting tissue and medical data from patients with inflammatory or invasive breast cancer
Inflammatory Breast Cancer (IBC) Registry
This study is collecting blood, tissue, and other samples from patients with inflammatory or invasive breast cancer to help researchers learn more about the disease and improve treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 10 sites (Gilbert, Arizona and 9 other locations) |
| Trial ID | NCT00477100 on ClinicalTrials.gov |
What this trial studies
This study focuses on the collection of biospecimens and medical data to create a research tissue registry for patients diagnosed with inflammatory or invasive breast cancer. It aims to gather various samples, including blood, tissue, and stool, along with clinical and imaging data from both newly diagnosed patients and those seeking further treatment. The collected data will be analyzed to improve understanding and treatment of inflammatory breast cancer. Patients will participate in interviews and complete questionnaires to provide comprehensive information.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with a clinical diagnosis of primary inflammatory breast cancer or those highly suspicious for it.
Not a fit: Patients with non-invasive breast cancer or those who have already undergone extensive treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for inflammatory breast cancer.
How similar studies have performed: Other studies have shown promise in utilizing biospecimen collection for cancer research, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with clinical diagnosis of primary inflammatory breast cancer (IBC), second primary IBC, or highly suspicious for IBC (MD Anderson patients only). * Histological diagnosis of invasive breast cancer, or highly suspicious for IBC (MD Anderson patients only) but pending breast cancer diagnosis. * Be either newly diagnosed, or highly suspicious for IBC (MD Anderson patients only) \[Cohort I\] or have paraffin blocks or up to 20 unstained slides of each representative block(s) from the time of initial diagnosis of IBC(i.e. core biopsy and punch biopsy) and/or from mastectomy (Cohort II-MD Anderson patients only) * Age \> 18 years * Able to provide informed consent Exclusion Criteria:
Where this trial is running
Gilbert, Arizona and 9 other locations
- Banner - MD Anderson Cancer Center — Gilbert, Arizona, United States (Recruiting)
- Scripps - MD Anderson Cancer Center — La Jolla, California, United States (Active_not_recruiting)
- Banner - MD Anderson Cancer Center - Northern Colorado — Greeley, Colorado, United States (Recruiting)
- Baptist - MD Anderson Cancer Center — Jacksonville, Florida, United States (Recruiting)
- Covenant Medical Center — Saginaw, Michigan, United States (Active_not_recruiting)
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
- MD Anderson in Katy — Houston, Texas, United States (Recruiting)
- MD Anderson League City — Nassau Bay, Texas, United States (Recruiting)
- MD Anderson in Sugar Land — Sugar Land, Texas, United States (Recruiting)
- MD Anderson in The Woodlands — The Woodlands, Texas, United States (Recruiting)
Study contacts
- Principal investigator: VIcente Valero, MD — M.D. Anderson Cancer Center
- Study coordinator: Jie Willey
- Email: jwilley@mdanderson.org
- Phone: 713-792-3965
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.